RegeneRx Biopharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.regenerx.com
Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 1
1 (20.0%)A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
Phase 2
Withdrawn
- Conditions
- ST Elevation Myocardial InfarctionAcute Myocardial InfarctionSTEMI
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Registration Number
- NCT01311518
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00832091
- Locations
- 🇮🇹
Chirurgia Vascolare, Bologna, Italy
🇮🇹Università degli Studi di Napoli - Federico II, Naples, Italy
🇮🇹Azienda Ospedaliera di Padova, Padova, Italy
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
Phase 1
Withdrawn
- Conditions
- Myocardial IschemiaMyocardial Infarction
- Interventions
- Other: Placebo
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Registration Number
- NCT00743769
- Locations
- 🇺🇸
Healthcare Discoveries LLC, San Antonio, Texas, United States
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2010-02-01
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00382174
- Locations
- 🇺🇸
Institute for Advanced Wound Care, Montgomery, Alabama, United States
🇺🇸Impact Clinical Trials, Beverly Hills, California, United States
🇺🇸Long Beach VAMC, Long Beach, California, United States
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00311766
News
No news found